HepatitisCvirus(HCV)infectionremainsoneofthemaincausesofchronicliverdiseaseworldwide.Theadventofdirect-actingantivirals(DAAs)hassignificantlyimprovedthecourseofpatientswithchronicHCVinfection(CHC),duetotheabilityofthesedrugstoachievehighratesofsustainedvirologicalresponse(SVR).TheseexceedinglyhighratesofSVRandtheexcellentsafetydatahavebeenconfirmedinreallifepractice.Evolvingguidelineshavebeenissuedbynationalandinternationalscientificsoci-etiesinaccordancewiththeprogressionofclinicalknowledgeandtheavailabilityofnewDAAs.Theserecommendations,however,maynotbeapplieduniversallybecauseofdelaysindrugsreimbursabilityindifferentcountriesandbecausesomeNationalHealthSystemsidentifyonlypatientswithadvanceddiseaseasatreatmentpriority.ItalyinthisregardisaprototypeaboutDAAstreatmentofCHCpatients.WiththeaimtoassesstheItaliantreatmentexperiencewithDAAsandtorespondtounmetneedsintreatmentoptimizationofantiviraltherapyinspecificsettingsofCHCpatients,agroupofItalianexpertsmetinStresainFebruary2017.Thesummaryoftheconsiderationsarisingfromthistwo-daymeetingandsomestatementsregardingafewopenissuesarereportedinthispositionpaper.©2017EditriceGastroenterologicaItalianaS.r.l.PublishedbyElsevierLtd.Allrightsreserved.
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel / Viganã², M., Perno, C.F., Craxã¬, A., Aghemo, A., Alberti, A., Andreone, P., Andreoni, M., Bonora, S., Brunetto, M.R., Bruno, R., Bruno, S., Calvaruso, V., Caporaso, N., Ceccherini-Silberstein, F., Cento, V., Ciancio, A., Colombatto, P., Degasperi, E., Di Marco, V., Di Perri, G., et al.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 49:7(2017), pp. 731-741. [10.1016/j.dld.2017.03.027]
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel
Caporaso, Nicola;Taliani, Gloria;
2017
Abstract
HepatitisCvirus(HCV)infectionremainsoneofthemaincausesofchronicliverdiseaseworldwide.Theadventofdirect-actingantivirals(DAAs)hassignificantlyimprovedthecourseofpatientswithchronicHCVinfection(CHC),duetotheabilityofthesedrugstoachievehighratesofsustainedvirologicalresponse(SVR).TheseexceedinglyhighratesofSVRandtheexcellentsafetydatahavebeenconfirmedinreallifepractice.Evolvingguidelineshavebeenissuedbynationalandinternationalscientificsoci-etiesinaccordancewiththeprogressionofclinicalknowledgeandtheavailabilityofnewDAAs.Theserecommendations,however,maynotbeapplieduniversallybecauseofdelaysindrugsreimbursabilityindifferentcountriesandbecausesomeNationalHealthSystemsidentifyonlypatientswithadvanceddiseaseasatreatmentpriority.ItalyinthisregardisaprototypeaboutDAAstreatmentofCHCpatients.WiththeaimtoassesstheItaliantreatmentexperiencewithDAAsandtorespondtounmetneedsintreatmentoptimizationofantiviraltherapyinspecificsettingsofCHCpatients,agroupofItalianexpertsmetinStresainFebruary2017.Thesummaryoftheconsiderationsarisingfromthistwo-daymeetingandsomestatementsregardingafewopenissuesarereportedinthispositionpaper.©2017EditriceGastroenterologicaItalianaS.r.l.PublishedbyElsevierLtd.Allrightsreserved.| File | Dimensione | Formato | |
|---|---|---|---|
|
Viganò_treatment-hepatitis_2017.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
813.58 kB
Formato
Adobe PDF
|
813.58 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
